Intestifix 001 placebo

DRUG2 trials

Sponsors

Universitaetsklinikum Heidelberg AöR, Universitaetsklinikum Aachen AöR

Conditions

Hepatocellular carcinomacirrhosis and ascites

Phase 2

Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab – A randomized, placebo-controlled, double-blind Phase II trial (FLORA)

RecruitingCTIS2023-506887-15-00

Universitaetsklinikum Heidelberg AöRHepatocellular carcinoma

Start: 2025-07-14Target: 48Updated: 2026-01-22

Encapsulated Fecal Microbiota Transfer to Treat Immune Activation in Patients with Cirrhosis and Ascites (TransImmune) – A randomized, double-blind, placebo-controlled phase IIa clinical pilot study

RecruitingCTIS2023-507790-18-00

Universitaetsklinikum Aachen AöRcirrhosis and ascites

Start: 2025-08-01Target: 24Updated: 2026-01-12

Related Papers

Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab – a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial)

BMJ Open2025-09-012 citations